The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection
© Henderson and Hope; licensee BioMed Central Ltd. 2006
Received: 15 April 2006
Accepted: 25 May 2006
Published: 25 May 2006
HIV entry occurs via membrane-mediated fusion of virus and target cells. Interactions between gp120 and cellular co-receptors lead to both the formation of fusion pores and release of the HIV genome into target cells. Studies using cell-cell fusion assays have demonstrated that a temperature-arrested state (TAS) can generate a stable intermediate in fusion related events. Other studies with MLV pseudotyped with HIV envelope also found that a temperature sensitive intermediate could be generated as revealed by the loss of a fluorescently labeled membrane. However, such an intermediate has never been analyzed in the context of virus infection. Therefore, we used virus-cell infection with replication competent HIV to gain insights into virus-cell fusion. We find that the TAS is an intermediate in the process culminating in the HIV infection of a target cell. In the virion-cell TAS, CD4 has been engaged, the heptad repeats of gp41 are exposed and the complex is kinetically predisposed to interact with coreceptor to complete the fusion event leading to infection.
The fusion process of HIV envelope (Env) is a highly concerted and cooperative process between viral particles and human target cells. HIV Env mediated fusion is initiated through gp120 interactions with cell surface CD4 . These interactions lead to conformational changes in Env, which expose binding sites to the principle cellular coreceptors CCR5 or CXCR4 . CD4 binding also induces conformational changes in the gp41 subunit of Env, leading to exposure of the N-terminal hydrophobic fusion peptide and the heptad repeats . The fusion peptide then inserts into the host cell plasma membrane, which brings the two membranes together to allow fusion. Recently, much attention has focused on events related to the fusion of viral and target cell membranes. These studies have provided insight into intermediate stages within the fusion process, which has led to the development of successful alternative drug therapies. For example, enfuvirtide (T-20) was recently approved for clinical treatment of HIV-1. T-20 is a peptide fusion inhibitor, which disrupts fusion by interacting with the N-terminal helical regions within gp41 to prevent six-helix bundle formation. Although enfuvirtide and other entry inhibitors utilize unique mechanisms to disrupt HIV entry, the virus can readily develop resistance to these compounds. Therefore, much remains to be elucidated regarding the kinetics and rate-limiting steps involved in viral fusion.
Much of the analysis of HIV fusion has been in the context of cell-cell based fusion assays. Typically, effector cells that express fusion proteins on their surface are coincubated with target cells expressing the appropriate receptor and coreceptors. Fusion between effector and target cells is measured by lipid or cytoplasmic content mixing . Although these assays provide valuable information regarding fusion, it is important to fully assess all the variables governing fusion of virions to their cellular targets because of differences between virion and cellular membranes.
Research has shown that the lipid composition and fluidity of the HIV envelope membrane is significantly different from that of the host cell plasma membrane . The HIV envelope membrane has an unusually high content of cholesterol and phospholipids . Other findings conclude that HIV preferentially selects lipid rich domains within the host cell plasma membrane for budding from and entry into host cells [5–7]. A number of studies also support the notion that the specificity of the viral envelope membrane plays a critical role in both entry and infection by HIV virions [5, 7]. Due to differences between the HIV envelope membrane as well as the plasma membrane of target cells, cell-cell fusion assays may not accurately reflect what happens during virion-cell fusion. Recently, Melikyan and colleagues were able to develop a pseudoviral-cell fusion system using time-resolved imaging of HIV-1 to monitor fusion of an individual virion to a cell . This assay was based on the observed loss of a fluorescent marker located in the virion membrane. When the virion and cell membrane merge, the viral membrane label is free to diffuse in the cell membrane. In this assay, fusion is scored by a loss of membrane. This approach can provide important insights into HIV entry. However, other studies reveal that lipid mixing can take place without the completion of the fusion process. For example, for the entry of rous sarcoma virus (RSV), lipid mixing is pH-independent, while the completion of the fusion process is pH-dependent . Further, the formation of a fusion pore appears to be reversible . Again lipid mixing can take place without the completion of the fusion process.
Considering the potential confounding aspects of lipid mixing assays and differences between virion-cell fusion and cell-cell fusion we explored the early events in HIV entry using viral infection as the readout of successful completion of the entry process. For this analysis we took advantage of the temperature arrested state which has been previously demonstrated to represent an intermediate step in the process of fusion mediated by the interaction of HIV envelope and cells expressing CD4 and coreceptor. These studies by Melikyan et. al. demonstrated that a temperature arrested state (TAS) can be created by pre-incubating effector cells expressing HIV envelope and target cells expressing CD4 and coreceptor at suboptimal temperatures before shifting to 37°C, which is permissive for fusion [9–11]. These studies revealed a rapid increase in the fusion kinetics of effector and target cells that were initially maintained at suboptimal temperatures, compared to those cells maintained at the biologically relevant temperature of 37°C [9, 11]. They found that during cell-cell fusion TAS, CD4 had been engaged and the heptad repeats in gp41 had been exposed, but coreceptor had not yet been engaged. Our analysis reveals that an analogous "temperature arrested state" can be generated for virion-cell fusion and that it is an intermediate in the process leading to HIV infection.
Exposure of the heptad repeats of gp41 is required for susceptibility to C34. We therefore wanted to determine when fusion became resistant to C34 during the 23°C incubation . We therefore conducted the following experiment where virus was allowed to bind cells at 4°C for 2 hours in the absence of drug. Virus was removed by washing with PBS and the cells where shifted to 23°C for 3 hours to establish TAS. In a subset of cells, we examined the ability of C34 or sCD4 to inhibit viral fusion when added in the first hour of 23°C-TAS ("before TAS") or in the last hour of 23°C-TAS ("after TAS). In either case the inhibitor was allowed 1 hour for binding and removed by washing. After 3 hours at 23°C-TAS, cells where shifted to 37°C to promote full fusion. 48 hours later infection was measured by β-gal activity. When C34 was added at the onset of TAS ("before TAS"), a minimal 20% reduction in fusion was observed, suggesting the heptad repeats of gp41 were not fully accessible during this time. However, a greater degree of inhibition was observed when C34 was added in the last hour ("after TAS") of 23°C-TAS, suggesting that the heptad repeats do eventually become accessible to the C34 peptide during TAS. Conversely, inhibition by sCD4 was only achieved when sCD4 was added at the onset of TAS and not in the last hour of TAS. This indicates that the step of sCD4 inhibition arises before TAS while the step of C34 inhibition arises after TAS has been established. Further, the lack of inhibition by C34 when added before 23°C-TAS implies that binding sites within gp41, to which C34 is reactive, are not exposed until after TAS has been established.
Other studies presented here demonstrate that virions in the TAS intermediate are kinetically predisposed to pass beyond a point where they are sensitive to inhibition by CXCR4 or CCR5 coreceptor antagonists (figure 2). The same is true for the fusion passing beyond a point where it is sensitive to inhibition by the C34 peptide (figure 3). The most simple interpretation of this finding is that the time needed for envelope to successfully engage cellular receptors is eliminated during the 23°C incubation. Therefore, the fusion complex can proceed directly to complete coreceptor engagement, and go on to fuse after shifting to 37°C. In contrast, virions incubated at 4°C for the same period are delayed in achieving resistance to coreceptor antagonists because they must take the time to properly engage CD4 before proceeding to engage a coreceptor. Coreceptor engagement following CD4 engagement has been demonstrated to take approximately 30 minutes [18, 19]. After 4 hours, any kinetic advantage imparted by the TAS is lost as virus-cell cultures become resistant to both coreceptor antagonists or C34 peptide, regardless of whether they were incubated at 23°C or 4°C (figure 2, 3B). The kinetics of resistance to downstream fusion inhibitors also demonstrates that TAS is an intermediary in the process leading to fusion and infection. It is possible that TAS represents a non-productive but reversible intermediate. However, reversion to the functional pathway would take time, resulting in the delay of fusion of virus-cell cultures maintained at TAS relative to control cells. Therefore, the kinetic predisposition of virus-cell cultures to advance beyond sensitivity to downstream inhibitors of fusion demonstrate that the TAS intermediate represents a discreet step in the fusion pathway which ultimately leads to HIV infection of target cells.
Comparing our findings using virus-cell interactions to previous studies using cell-cell based fusion assays reveals a difference between the cell-cell TAS and virus-cell TAS at the level of engagement of the CXCR4 coreceptor. In the cell-cell based assays, there is a significant and detectable engagement of the coreceptor shown by resistance to the CXCR4 binding peptide T22 . Likewise, significant resistance to AMD3100 for blocking CXCR4 mediated fusion after incubation at 23°C for 2 hours is also observed. Furthermore, Mkrtchyan has shown that the longer the incubation period, the greater the extent of resistance . In contrast, we have shown that incubation of virus and target cells at 23°C after 2–3 hours confers negligible resistance to AMD3100. Conversely, our studies with CCR5 tropic envelope in the virus-cell TAS, mimicked previous findings using a TAS for cell-cell fusion assays. For example, resistance to TAK779 was 20% after incubation at 23°C (figure 2C) similar to the cell-cell fusion studies. One possible explanation for this difference lies in the mobilities of the chemokine receptors in the membrane. We have previously reported that CCR5 is highly mobile in the membrane . In contrast, we have recently found that CXCR4 in much less mobile . The highly mobile CCR5 can begin to engage the CD4 bound HIV envelope at 23°C while the less mobile CXCR4 can not. The mobility of CXCR4 is less important in the case of the cell-cell assays because it would be recruited to the site of cell-cell contact within minutes of the shift to 37°C, as has been reported for the virological synapse. It has previously been shown that receptor/co-receptor density plays a role in the rate of HIV fusion and infection , and that multiple receptor and co-receptor molecules must engage multiple gp120 subunits in order to initiate fusion . The formation of a virological synapse recruits CXCR4 and increases the rate of these engagements. The difference observed in virus-cell interactions suggests that CXCR4 is not actively recruited to the site of virus binding at the same rate.
Studies by Kabat's laboratory suggest that CCR5 entry is governed by three kinetic processes. One of these processes includes the formation of 'competent complexes.' These 'competent complexes' consist of sufficient CCR5-gp120 associations that are capable of proceeding further into the fusion process. The TAS intermediate reveals that the interaction with chemokine receptor is the rate-limiting step in the process of the formation of these 'competent complexes'. Potential temperature sensitive steps might actually be differences in chemokine mobility or affinity to the HIV envelope. It is unlikely that the temperature sensitive step is associated with conformational changes known to take place in HIV envelope because of the differences observed between cell-cell TAS and virus-cell TAS described above. The TAS intermediate described here allows the HIV-1 fusion reaction to be analyzed in the context of infectious HIV-1 particles and their respective target cells. Using suboptimal temperatures, we can gain valuable insight into HIV-1 virus-cell fusion kinetics. Ultimately, generating a temperature-arrested intermediate for virus-cell fusion provides a useful tool for synchronizing entry and studying HIV-1 fusion microscopically.
Materials and methods
Virus-cell fusion/infection assays
In order to study virus-cell fusion, we developed a system that allows fusion to be assayed in the context of infectious virions that were preincubated with target cells. The Magi reporter cell line for viral infection was employed . Magi +/+ cells derive from HeLa cells and stably express CD4 and CXCR4 on the cells surface. Magi +/+ cells also contain a stably integrated copy of the β-galactosidase (β-gal) gene downstream of the HIV-1 long terminal repeat (LTR). Upon infection, the HIV transactivator protein Tat activates β-gal expression. Therefore, viral fusion leads to β-gal expression and the level of β-gal activity can be measured from infected cells . 36 hours post infection, cells were lysed in sodium phosphate buffer with 0.2% Triton X and assayed for β-gal expression. β-Gal expression was quantified by monitoring cleavage of the colorimetric β-gal substrate o-nitrophenyl-β-D-galactopyranoside (ONPG) using a 96-well microplate reader measuring absorbance at 405 nm. The average background values of uninfected cells were subtracted from the values of infected cells. Varying temperatures were maintained using the Eppendorf Centrifuge 5810 R. Using this system, we manipulated temperature conditions during virus-cell incubation and used fusion inhibitors to explore kinetic factors influencing HIV-1 entry.
Cell culture and virus production
Magi +/+ cells were grown in Dulbecco's modified Eagle's growth medium (BioWhittaker, Walerville, Md.), which contained 10% fetal bovine serum and 1% penicillin-streptomycin-glutamine. Virus was produced by CaPO4 transfection of 293T cells with 20 μg of HIV-1Bru or HIV-1JRFL proviral constructs. Two days following transfection, virus was harvested through a 0.45 μm pore sized filter.
This work was supported by National Institutes of Health Grant RO1-AI5205 to TJH. TJH is an Elizabeth Glaser Scientist. We thank the contributors to the NIH AIDS Reagent Program for materials, especially the C34 peptide and AMD 3100. PRO 542 was obtained from Progenics Pharmeceuticals.
- Doms RW, Moore JP: HIV-1 membrane fusion: targets of opportunity. J Cell Biol 2000, 151: F9-14. 10.1083/jcb.151.2.F9PubMed CentralView ArticlePubMedGoogle Scholar
- Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384: 184-7. 10.1038/384184a0View ArticlePubMedGoogle Scholar
- Markosyan RM, Cohen FS, Melikyan GB: Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane. Mol Biol Cell 2005, 16: 5502-13. 10.1091/mbc.E05-06-0496PubMed CentralView ArticlePubMedGoogle Scholar
- Aloia RC, Tian H, Jensen FC: Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci USA 1993, 90: 5181-5. 10.1073/pnas.90.11.5181PubMed CentralView ArticlePubMedGoogle Scholar
- Guyader M, Kiyokawa E, Abrami L, Turelli P, Trono D: Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol 2002, 76: 10356-64. 10.1128/JVI.76.20.10356-10364.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Nguyen DH, Hildreth JE: Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000, 74: 3264-72. 10.1128/JVI.74.7.3264-3272.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Popik W, Alce TM, Au WC: Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 2002, 76: 4709-22. 10.1128/JVI.76.10.4709-4722.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Mothes W, Boerger AL, Narayan S, Cunningham JM, Young JA: Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell 2000, 103: 679-89. 10.1016/S0092-8674(00)00170-7View ArticlePubMedGoogle Scholar
- Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS: Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000, 151: 413-23. 10.1083/jcb.151.2.413PubMed CentralView ArticlePubMedGoogle Scholar
- Frey S, Marsh M, Gunther S, Pelchen-Matthews A, Stephens P, Ortlepp S, Stegmann T: Temperature dependence of cell-cell fusion induced by the envelope glycoprotein of human immunodeficiency virus type 1. J Virol 1995, 69: 1462-72.PubMed CentralPubMedGoogle Scholar
- Gallo SA, Clore GM, Louis JM, Bewley CA, Blumenthal R: Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41. Biochemistry 2004, 43: 8230-3. 10.1021/bi049957vView ArticlePubMedGoogle Scholar
- Chan DC, Chutkowski CT, Kim PS: Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998, 95: 15613-7. 10.1073/pnas.95.26.15613PubMed CentralView ArticlePubMedGoogle Scholar
- Malashkevich VN, Chan DC, Chutkowski CT, Kim PS: Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci USA 1998, 95: 9134-9. 10.1073/pnas.95.16.9134PubMed CentralView ArticlePubMedGoogle Scholar
- Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994, 91: 9770-4. 10.1073/pnas.91.21.9770PubMed CentralView ArticlePubMedGoogle Scholar
- Mkrtchyan SR, Markosyan RM, Eadon MT, Moore JP, Melikyan GB, Cohen FS: Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol 2005, 79: 11161-9. 10.1128/JVI.79.17.11161-11169.2005PubMed CentralView ArticlePubMedGoogle Scholar
- He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, Weiss CD: Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003, 77: 1666-71. 10.1128/JVI.77.3.1666-1671.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Abrahamyan LG, Mkrtchyan SR, Binley J, Lu M, Melikyan GB, Cohen FS: The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol 2005, 79: 106-15. 10.1128/JVI.79.1.106-115.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R: The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003, 1614: 36-50. 10.1016/S0005-2736(03)00161-5View ArticlePubMedGoogle Scholar
- Gallo SA, Puri A, Blumenthal R: HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry 2001, 40: 12231-6. 10.1021/bi0155596View ArticlePubMedGoogle Scholar
- Steffens CM, Hope TJ: Localization of CD4 and CCR5 in living cells. J Virol 2003, 77: 4985-91. 10.1128/JVI.77.8.4985-4991.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Anderson A, Hope TJ: personal communication.Google Scholar
- Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002, 99: 16249-54. 10.1073/pnas.252469399PubMed CentralView ArticlePubMedGoogle Scholar
- Kuhmann SE, Platt EJ, Kozak SL, Kabat D: Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 2000, 74: 7005-15. 10.1128/JVI.74.15.7005-7015.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Kimpton J, Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992, 66: 2232-9.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.